nitrofurantoin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
NO2 - derivatives	1949	67-20-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nitrofurantoin sodium nitrofurantoin furadantin furadantoin nitrofurantoin, macrocrystalline nitrofurantoin monohydrate	A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression. Molecular weight: 238.16 Formula: C8H6N4O5 CLOGP: -0.47 LIPINSKI: 0 HAC: 9 HDO: 1 TPSA: 120.73 ALOGS: -2.76 ROTB: 3 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nitrofurantoin sodium
nitrofurantoin
furadantin
furadantoin
nitrofurantoin, macrocrystalline
nitrofurantoin monohydrate

A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.

Molecular weight: 238.16
Formula: C8H6N4O5
CLOGP: -0.47
LIPINSKI: 0
HAC: 9
HDO: 1
TPSA: 120.73
ALOGS: -2.76
ROTB: 3

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
0.20	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	0.19 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	47 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	24 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	87 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.57 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	9.70 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.17 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.97 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 6, 1953	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	303.20	10.29	536	32970	223484	50348134
Autoimmune hepatitis	208.13	10.29	101	33405	7418	50564200
Drug ineffective	131.06	10.29	214	33292	819119	49752499
Drug hypersensitivity	122.80	10.29	405	33101	250605	50321013
Jaundice	121.05	10.29	116	33390	26313	50545305
Pulmonary toxicity	100.14	10.29	56	33450	5506	50566112
Cystitis	82.23	10.29	123	33383	44441	50527177
Contraindicated product administered	78.85	10.29	5	33501	148953	50422665
Drug-induced liver injury	78.60	10.29	95	33411	28000	50543618
Infusion related reaction	73.58	10.29	12	33494	169545	50402073
Pulmonary fibrosis	72.26	10.29	85	33421	24352	50547266
Synovitis	69.18	10.29	3	33503	123862	50447756
Lip swelling	63.33	10.29	80	33426	24656	50546962
Rheumatoid arthritis	57.86	10.29	31	33475	202519	50369099
Systemic lupus erythematosus	54.61	10.29	13	33493	140609	50431009
Hand deformity	54.11	10.29	3	33503	100196	50471422
Therapeutic product effect decreased	53.98	10.29	12	33494	136038	50435580
Interstitial lung disease	52.91	10.29	112	33394	53064	50518554
Drug intolerance	52.42	10.29	41	33465	219063	50352555
Off label use	51.45	10.29	153	33353	474273	50097345
Glossodynia	44.25	10.29	11	33495	115558	50456060
Oesophageal spasm	43.75	10.29	24	33482	2272	50569346
Systemic inflammatory response syndrome	43.64	10.29	32	33474	5017	50566601
Heart sounds	42.77	10.29	16	33490	614	50571004
Arthropathy	41.09	10.29	27	33479	157879	50413739
Prolonged expiration	40.67	10.29	16	33490	705	50570913
Injury	39.66	10.29	95	33411	48830	50522788
Oesophageal pain	39.30	10.29	24	33482	2778	50568840
Malaise	38.19	10.29	364	33142	335168	50236450
Wound	35.20	10.29	13	33493	105781	50465837
Treatment failure	35.18	10.29	24	33482	137613	50434005
Multiple sclerosis	34.18	10.29	54	33452	20439	50551179
Hepatic fibrosis	33.96	10.29	23	33483	3179	50568439
Pericarditis	33.16	10.29	6	33500	78683	50492935
Joint swelling	32.78	10.29	71	33435	245215	50326403
Liver function test abnormal	31.63	10.29	82	33424	44257	50527361
Swollen tongue	30.45	10.29	62	33444	28568	50543050
Rales	28.32	10.29	34	33472	9944	50561674
Costovertebral angle tenderness	27.97	10.29	7	33499	65	50571553
Hallucination	27.05	10.29	80	33426	46577	50525041
Alopecia	26.50	10.29	79	33427	244968	50326650
Abdominal discomfort	26.27	10.29	73	33433	231568	50340050
Drug reaction with eosinophilia and systemic symptoms	26.12	10.29	58	33448	28366	50543252
Lymphoedema	25.75	10.29	31	33475	9091	50562527
Acute hepatic failure	25.72	10.29	41	33465	15636	50555982
Product use issue	25.62	10.29	37	33469	149438	50422180
Hypersensitivity pneumonitis	25.39	10.29	17	33489	2305	50569313
Bladder disorder	25.27	10.29	28	33478	7515	50564103
Hepatic cirrhosis	24.85	10.29	43	33463	17534	50554084
Pyelonephritis	24.31	10.29	39	33467	14950	50556668
Change of bowel habit	24.31	10.29	15	33491	1769	50569849
Musculoskeletal stiffness	23.85	10.29	30	33476	128451	50443167
Chromaturia	23.72	10.29	38	33468	14552	50557066
Urosepsis	23.41	10.29	39	33467	15426	50556192
Eosinophilia	23.01	10.29	43	33463	18609	50553009
Cystitis interstitial	22.89	10.29	13	33493	1316	50570302
Cholecystitis chronic	22.75	10.29	30	33476	9639	50561979
Respiration abnormal	22.61	10.29	22	33484	5080	50566538
Emotional distress	22.52	10.29	55	33451	28608	50543010
Atrioventricular block first degree	22.49	10.29	24	33482	6177	50565441
Febrile neutropenia	22.43	10.29	19	33487	97648	50473970
Drug abuse	22.32	10.29	6	33500	59840	50511778
Pollakiuria	22.29	10.29	49	33457	23802	50547816
Neurogenic bladder	22.22	10.29	17	33489	2840	50568778
Liver transplant	21.86	10.29	15	33491	2117	50569501
Urine odour abnormal	21.65	10.29	22	33484	5351	50566267
Hepatic enzyme increased	21.64	10.29	36	33470	137344	50434274
Kidney infection	21.62	10.29	42	33464	18704	50552914
Swelling	21.53	10.29	65	33441	200807	50370811
Multiple sclerosis relapse	21.51	10.29	70	33436	42894	50528724
Hepatitis	21.24	10.29	57	33449	31396	50540222
Appetite disorder	21.01	10.29	23	33483	6091	50565527
Jaundice cholestatic	20.72	10.29	21	33485	5090	50566528
Depressive symptom	20.52	10.29	17	33489	3183	50568435
Hiccups	19.67	10.29	13	33493	1726	50569892
Dysuria	19.59	10.29	52	33454	28452	50543166
Arthralgia	19.55	10.29	191	33315	438511	50133107
Amblyopia	19.54	10.29	7	33499	237	50571381
Acute febrile neutrophilic dermatosis	18.99	10.29	15	33491	2627	50568991
Fracture displacement	18.97	10.29	11	33495	1158	50570460
Anhedonia	18.58	10.29	27	33479	9497	50562121
Colour blindness acquired	18.31	10.29	5	33501	67	50571551
Rectal polyp	18.19	10.29	10	33496	951	50570667
Death	17.91	10.29	134	33372	325245	50246373
Nephrolithiasis	17.79	10.29	57	33449	34636	50536982
Sinusitis	17.70	10.29	56	33450	170502	50401116
Pseudophaeochromocytoma	17.67	10.29	5	33501	77	50571541
Irritable bowel syndrome	17.65	10.29	6	33500	51435	50520183
Abdominal rigidity	17.50	10.29	12	33494	1692	50569926
Swelling face	17.39	10.29	75	33431	52520	50519098
Rash macular	17.34	10.29	39	33467	19238	50552380
Neutropenia	17.23	10.29	46	33460	147919	50423699
Flank pain	17.14	10.29	31	33475	13084	50558534
Subacute cutaneous lupus erythematosus	16.84	10.29	13	33493	2202	50569416
Chronic hepatitis	16.61	10.29	9	33497	831	50570787
Therapeutic product effect incomplete	16.33	10.29	22	33484	91493	50480125
Therapy interrupted	16.18	10.29	39	33467	20113	50551505
Hepatitis acute	16.16	10.29	23	33483	7938	50563680
Cholelithiasis	15.64	10.29	58	33448	37915	50533703
Ureteric obstruction	15.63	10.29	11	33495	1617	50570001
Discomfort	15.62	10.29	30	33476	108350	50463268
Lower urinary tract symptoms	15.54	10.29	4	33502	42	50571576
Oesophageal cancer metastatic	15.51	10.29	5	33501	122	50571496
Muscle injury	15.27	10.29	3	33503	37108	50534510
Eosinophilic pleural effusion	15.21	10.29	4	33502	46	50571572
Hepatic necrosis	15.09	10.29	18	33488	5230	50566388
Tubulointerstitial nephritis	15.07	10.29	32	33474	15179	50556439
Retroperitoneal fibrosis	14.79	10.29	6	33500	287	50571331
Cardiac murmur	14.75	10.29	26	33480	10758	50560860
Intestinal haemorrhage	14.63	10.29	14	33492	3166	50568452
Folliculitis	14.50	10.29	4	33502	39221	50532397
Peripheral swelling	14.28	10.29	79	33427	205857	50365761
Escherichia urinary tract infection	14.13	10.29	25	33481	10370	50561248
Gallbladder disorder	14.09	10.29	33	33473	16709	50554909
Haematuria	13.98	10.29	43	33463	25570	50546048
Nail infection	13.71	10.29	11	33495	1970	50569648
Sensitisation	13.61	10.29	10	33496	1572	50570046
Chronic kidney disease	13.36	10.29	57	33449	39714	50531904
Intentional overdose	13.34	10.29	13	33493	62491	50509127
Bladder irritation	13.05	10.29	5	33501	205	50571413
Product contamination microbial	13.05	10.29	5	33501	205	50571413
Fluid intake reduced	12.97	10.29	13	33493	3109	50568509
Lichen sclerosus	12.71	10.29	8	33498	977	50570641
Wheezing	12.48	10.29	77	33429	61970	50509648
Reperfusion arrhythmia	12.42	10.29	5	33501	234	50571384
Overdose	12.38	10.29	30	33476	99697	50471921
Leukocyturia	12.29	10.29	8	33498	1035	50570583
Hydronephrosis	12.21	10.29	21	33485	8520	50563098
Hyperhidrosis	12.17	10.29	101	33405	89325	50482293
Traumatic lung injury	12.15	10.29	9	33497	1432	50570186
Weight increased	12.14	10.29	81	33425	201810	50369808
Rash	12.13	10.29	377	33129	437094	50134524
Liver injury	12.04	10.29	40	33466	24766	50546852
Clostridium difficile colitis	11.82	10.29	32	33474	17710	50553908
Traumatic liver injury	11.66	10.29	5	33501	275	50571343
Urinary retention	11.63	10.29	41	33465	26149	50545469
Therapy non-responder	11.62	10.29	10	33496	51012	50520606
Urinary incontinence	11.54	10.29	43	33463	28165	50543453
Urinary tract infection bacterial	11.52	10.29	14	33492	4145	50567473
Tracheo-oesophageal fistula	11.34	10.29	6	33500	528	50571090
Granulomatous pneumonitis	11.22	10.29	3	33503	37	50571581
Reflexes abnormal	11.21	10.29	6	33500	541	50571077
Therapeutic response decreased	11.07	10.29	9	33497	47222	50524396
Urine analysis abnormal	11.02	10.29	14	33492	4336	50567282
Helicobacter infection	11.01	10.29	10	33496	49692	50521926
Knee arthroplasty	10.95	10.29	5	33501	35841	50535777
Frustration tolerance decreased	10.94	10.29	16	33490	5658	50565960
Feelings of worthlessness	10.93	10.29	5	33501	321	50571297
Pyrexia	10.89	10.29	329	33177	379874	50191744
Anaemia neonatal	10.86	10.29	5	33501	326	50571292
Walking aid user	10.79	10.29	17	33489	6416	50565202
Retinopathy of prematurity	10.77	10.29	5	33501	332	50571286
Anaemia	10.76	10.29	111	33395	252345	50319273
Hyponatraemia	10.74	10.29	104	33402	96035	50475583
Chest discomfort	10.70	10.29	101	33405	92621	50478997
Product use in unapproved indication	10.67	10.29	40	33466	115779	50455839
Completed suicide	10.62	10.29	48	33458	131841	50439777
Coagulopathy	10.62	10.29	31	33475	17913	50553705
Infection	10.59	10.29	69	33437	172885	50398733
Blood alkaline phosphatase increased	10.53	10.29	51	33455	37475	50534143
Vaginal discharge	10.43	10.29	15	33491	5225	50566393
Hepatic encephalopathy	10.40	10.29	21	33485	9615	50562003
Injection site pruritus	10.38	10.29	7	33499	40404	50531214
Sleep disorder due to a general medical condition	10.38	10.29	18	33488	7353	50564265
Coating in mouth	10.35	10.29	4	33502	168	50571450

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	96.76	16.57	91	5422	72263	29496751
Exposure during pregnancy	74.80	16.57	35	5478	8519	29560495
Urosepsis	35.18	16.57	23	5490	10723	29558291
Pulmonary fibrosis	33.94	16.57	26	5487	15556	29553458
Prostatitis	31.38	16.57	16	5497	4681	29564333
Protein total abnormal	31.11	16.57	8	5505	318	29568696
Pulmonary valve stenosis	30.30	16.57	8	5505	353	29568661
Skin depigmentation	29.58	16.57	8	5505	387	29568627
Cardiac murmur	28.86	16.57	17	5496	6596	29562418
Tendonitis	25.96	16.57	17	5496	7944	29561070
Hair colour changes	25.36	16.57	10	5503	1601	29567413
Culture urine positive	24.76	16.57	9	5504	1154	29567860
Porphyria non-acute	23.89	16.57	7	5506	454	29568560
Melanocytic naevus	23.74	16.57	10	5503	1896	29567118
Tooth injury	23.73	16.57	8	5505	822	29568192
Atrial septal defect	23.37	16.57	15	5498	6774	29562240
Open reduction of fracture	23.18	16.57	5	5508	91	29568923
Breast inflammation	22.72	16.57	4	5509	23	29568991
Haematuria	22.53	16.57	34	5479	44105	29524909
Patent ductus arteriosus	21.89	16.57	11	5502	3120	29565894
Plantar fasciitis	20.34	16.57	8	5505	1273	29567741
Eye swelling	20.07	16.57	15	5498	8642	29560372
Foetal exposure during pregnancy	20.06	16.57	28	5485	33839	29535175
Blood chromogranin A increased	19.46	16.57	5	5508	198	29568816
Gastric ulcer	19.32	16.57	18	5495	14043	29554971
Multiple congenital abnormalities	18.81	16.57	6	5507	518	29568496
Carcinoid crisis	18.69	16.57	5	5508	232	29568782
Skin exfoliation	18.57	16.57	22	5491	22623	29546391
Therapy interrupted	18.27	16.57	14	5499	8372	29560642
Bone neoplasm	17.96	16.57	5	5508	270	29568744
Neuroendocrine tumour	17.40	16.57	6	5507	660	29568354
Pulmonary toxicity	17.32	16.57	11	5502	4879	29564135
Craniosynostosis	17.32	16.57	5	5508	308	29568706
Chromaturia	16.85	16.57	16	5497	12786	29556228

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Urinary tract infection	338.71	11.02	497	32291	231099	64234845
Autoimmune hepatitis	193.47	11.02	97	32691	9987	64455957
Drug hypersensitivity	125.99	11.02	333	32455	237482	64228462
Pulmonary toxicity	120.59	11.02	67	32721	8494	64457450
Pulmonary fibrosis	107.56	11.02	102	32686	29776	64436168
Jaundice	86.85	11.02	115	32673	48397	64417547
Cystitis	85.56	11.02	107	32681	42568	64423376
Drug-induced liver injury	79.29	11.02	109	32679	47534	64418410
Lip swelling	73.75	11.02	86	32702	31821	64434123
Drug ineffective	68.77	11.02	210	32578	840037	63625907
Malaise	62.48	11.02	379	32409	395868	64070076
Oesophageal spasm	56.54	11.02	27	32761	2498	64463446
Off label use	55.42	11.02	153	32635	632653	63833291
Drug abuse	49.35	11.02	5	32783	132369	64333575
Infusion related reaction	48.39	11.02	12	32776	164455	64301489
Oesophageal pain	47.22	11.02	26	32762	3237	64462707
Rash	46.30	11.02	394	32394	458155	64007789
Interstitial lung disease	44.83	11.02	130	32658	97602	64368342
Heart sounds	43.67	11.02	15	32773	588	64465356
Urosepsis	43.63	11.02	55	32733	22039	64443905
Systemic inflammatory response syndrome	42.78	11.02	38	32750	10197	64455747
Hypersensitivity pneumonitis	39.35	11.02	23	32765	3209	64462735
Prolonged expiration	39.11	11.02	15	32773	808	64465136
Injury	37.61	11.02	86	32702	55906	64410038
Liver function test abnormal	37.45	11.02	89	32699	59312	64406632
Lymphoedema	35.99	11.02	34	32754	9871	64456073
Multiple sclerosis	35.59	11.02	46	32742	18895	64447049
Febrile neutropenia	34.39	11.02	27	32761	187630	64278314
Contraindicated product administered	33.44	11.02	7	32781	107822	64358122
Bladder disorder	32.78	11.02	29	32759	7738	64458206
Swollen tongue	32.04	11.02	61	32727	34893	64431051
Hallucination	31.63	11.02	95	32693	72693	64393251
Death	30.51	11.02	134	32654	482571	63983373
Rheumatoid arthritis	29.65	11.02	24	32764	164270	64301674
Swelling face	28.38	11.02	80	32708	59086	64406858
Hepatic fibrosis	28.08	11.02	23	32765	5529	64460415
Pyelonephritis	27.96	11.02	39	32749	17227	64448717
Therapeutic product effect decreased	27.63	11.02	12	32776	115339	64350605
Urine odour abnormal	27.51	11.02	22	32766	5114	64460830
Liver injury	27.14	11.02	52	32736	29880	64436064
Rales	25.56	11.02	35	32753	15194	64450750
Chromaturia	25.24	11.02	43	32745	22568	64443376
Neurogenic bladder	24.90	11.02	18	32770	3601	64462343
Neutropenia	24.78	11.02	53	32735	239571	64226373
Drug reaction with eosinophilia and systemic symptoms	24.73	11.02	72	32716	54145	64411799
Completed suicide	24.59	11.02	48	32740	224366	64241578
Fracture displacement	24.45	11.02	12	32776	1179	64464765
Change of bowel habit	23.64	11.02	15	32773	2423	64463521
Cholecystitis chronic	23.09	11.02	26	32762	9261	64456683
Culture urine positive	22.70	11.02	18	32770	4133	64461811
Therapy interrupted	22.23	11.02	38	32750	19998	64445946
Costovertebral angle tenderness	22.16	11.02	7	32781	210	64465734
Multiple sclerosis relapse	22.10	11.02	58	32730	41077	64424867
Amblyopia	21.95	11.02	7	32781	217	64465727
Hand deformity	21.83	11.02	3	32785	62768	64403176
Hepatic cirrhosis	21.80	11.02	44	32744	26254	64439690
Toxicity to various agents	21.69	11.02	103	32685	363410	64102534
Respiration abnormal	21.66	11.02	21	32767	6294	64459650
Dysuria	21.28	11.02	58	32730	41999	64423945
Acute hepatic failure	20.83	11.02	43	32745	26069	64439875
Drug intolerance	20.78	11.02	40	32748	187952	64277992
Hepatitis	20.28	11.02	60	32728	45522	64420422
Emotional distress	19.55	11.02	51	32737	35987	64429957
Urinary tract infection bacterial	19.41	11.02	18	32770	5103	64460841
Cystitis interstitial	19.13	11.02	10	32778	1122	64464822
Intentional overdose	19.07	11.02	11	32777	89933	64376011
Pollakiuria	18.54	11.02	46	32742	31484	64434460
Overdose	18.47	11.02	33	32755	159533	64306411
Flank pain	18.35	11.02	31	32757	16158	64449786
Product use in unapproved indication	18.30	11.02	39	32749	176579	64289365
Femur fracture	18.21	11.02	48	32740	34087	64431857
Pseudophaeochromocytoma	18.15	11.02	5	32783	92	64465852
Rectal polyp	17.95	11.02	10	32778	1274	64464670
Jaundice cholestatic	17.78	11.02	22	32766	8648	64457296
Appetite disorder	17.64	11.02	19	32769	6442	64459502
Depressive symptom	17.42	11.02	16	32772	4480	64461464
Acute febrile neutrophilic dermatosis	17.28	11.02	14	32774	3315	64462629
Colour blindness acquired	17.22	11.02	5	32783	112	64465832
Nail infection	17.01	11.02	11	32777	1836	64464108
Atrioventricular block first degree	17.01	11.02	24	32764	10710	64455234
Arthropathy	16.90	11.02	22	32766	120945	64344999
Tendonitis	16.89	11.02	34	32754	20248	64445696
Anaemia	16.84	11.02	118	32670	378562	64087382
Eosinophilia	16.82	11.02	50	32738	38026	64427918
Liver transplant	16.72	11.02	15	32773	4077	64461867
Prostatitis	16.30	11.02	14	32774	3592	64462352
Kidney infection	16.18	11.02	31	32757	17807	64448137
Haematuria	15.96	11.02	67	32721	60404	64405540
Gallbladder disorder	15.95	11.02	30	32758	17000	64448944
Vomiting	15.84	11.02	379	32409	550738	63915206
Pericarditis	15.79	11.02	6	32782	62510	64403434
Systemic lupus erythematosus	15.74	11.02	10	32778	77602	64388342
Abdominal rigidity	15.69	11.02	12	32776	2615	64463329
Hepatitis acute	15.66	11.02	26	32762	13363	64452581
Treatment failure	15.56	11.02	22	32766	116794	64349150
Lichen sclerosus	15.38	11.02	8	32780	889	64465055
Chronic hepatitis	15.37	11.02	9	32779	1259	64464685
Sensitisation	15.19	11.02	10	32778	1721	64464223
Urticaria	15.01	11.02	127	32661	147190	64318754
Frustration tolerance decreased	14.97	11.02	17	32771	6108	64459836
Urine leukocyte esterase positive	14.95	11.02	13	32775	3390	64462554
Escherichia urinary tract infection	14.92	11.02	24	32764	12013	64453931
Hypotension	14.91	11.02	123	32665	380851	64085093
Lower urinary tract symptoms	14.53	11.02	5	32783	197	64465747
Product use issue	14.50	11.02	35	32753	151680	64314264
Nephrolithiasis	14.47	11.02	52	32736	43631	64422313
Mass	14.42	11.02	27	32761	15249	64450695
Ureteric obstruction	14.32	11.02	11	32777	2411	64463533
Subacute cutaneous lupus erythematosus	14.19	11.02	12	32776	3013	64462931
Cholelithiasis	14.09	11.02	53	32735	45453	64420491
Porphyria non-acute	14.01	11.02	7	32781	714	64465230
Vision blurred	13.91	11.02	86	32702	90230	64375714
Bladder irritation	13.88	11.02	5	32783	226	64465718
Cardio-respiratory arrest	13.64	11.02	18	32770	98375	64367569
Oesophageal cancer metastatic	13.59	11.02	5	32783	240	64465704
Rash macular	13.34	11.02	34	32754	23651	64442293
Protein total abnormal	13.22	11.02	6	32782	494	64465450
Vaginal discharge	13.16	11.02	13	32775	3984	64461960
Calculus bladder	13.08	11.02	8	32780	1212	64464732
Tracheo-oesophageal fistula	12.99	11.02	6	32782	515	64465429
Breast inflammation	12.96	11.02	4	32784	111	64465833
Genital burning sensation	12.90	11.02	5	32783	277	64465667
Nausea	12.79	11.02	504	32284	785296	63680648
Wound	12.78	11.02	12	32776	76465	64389479
Reperfusion arrhythmia	12.73	11.02	5	32783	287	64465657
Traumatic lung injury	12.73	11.02	10	32778	2266	64463678
Wheezing	12.58	11.02	77	32711	80502	64385442
Organising pneumonia	12.54	11.02	19	32769	9036	64456908
Tinnitus	12.49	11.02	42	32746	34091	64431853
Urine analysis abnormal	12.44	11.02	15	32773	5741	64460203
Retroperitoneal fibrosis	12.42	11.02	6	32782	569	64465375
Skin depigmentation	12.35	11.02	7	32781	921	64465023
Therapeutic product effect incomplete	12.34	11.02	21	32767	103461	64362483
Vulvovaginal swelling	12.22	11.02	5	32783	320	64465624
Sinusitis	12.18	11.02	36	32752	145892	64320052
Paraesthesia oral	12.13	11.02	23	32765	13108	64452836
Muscle spasms	12.03	11.02	117	32671	140906	64325038
Cough	12.00	11.02	218	32570	301930	64164014
Fluid intake reduced	11.98	11.02	14	32774	5186	64460758
Nail disorder	11.81	11.02	18	32770	8606	64457338
Chest discomfort	11.77	11.02	100	32688	116006	64349938
Walking aid user	11.40	11.02	15	32773	6266	64459678
Blood chromogranin A increased	11.40	11.02	5	32783	380	64465564
Leukocyturia	11.39	11.02	8	32780	1530	64464414
Weight increased	11.27	11.02	63	32725	213285	64252659
Decreased interest	11.20	11.02	11	32777	3349	64462595
Urinary retention	11.08	11.02	52	32736	49149	64416795
Hepatitis chronic active	11.05	11.02	4	32784	183	64465761
Blood urine present	11.04	11.02	27	32761	18313	64447631

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01XE01	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives
ATC	J01XE51	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Nitrofuran derivatives
FDA CS	M0014892	Nitrofurans
FDA EPC	N0000175494	Nitrofuran Antibacterial
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000892	Anti-Infective Agents, Urinary
CHEBI has role	CHEBI:35441	antiinfective agents
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:50908	agente hepatotoxico

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Klebsiella cystitis	indication	60867007
Escherichia coli urinary tract infection	indication	301011002
Staphylococcus Saprophyticus Urinary Tract Infection	indication
Enterobacter Cystitis	indication
Enterococcus Urinary Tract Infection	indication
Staphylococcus Aureus Urinary Tract Infection	indication
Prevention of Bacterial Urinary Tract Infection	off-label use
Anuria	contraindication	2472002	DOID:2983
Acute hepatitis	contraindication	37871000
Vitamin B deficiency	contraindication	47903000
Fibrosis of lung	contraindication	51615001	DOID:3770
Obstructive hyperbilirubinemia	contraindication	59848001
Interstitial pneumonia	contraindication	64667001
Optic neuritis	contraindication	66760008	DOID:1210
Diabetes mellitus	contraindication	73211009	DOID:9351
Chronic hepatitis	contraindication	76783007	DOID:2237
Oliguria	contraindication	83128009
Cholestatic hepatitis	contraindication	95556007
Anemia due to enzyme deficiency	contraindication	111577008
Deficiency of glucose-6-phosphate dehydrogenase	contraindication	124134002	DOID:2862
Cobalamin deficiency	contraindication	190634004
Impaired renal function disorder	contraindication	197663003
Drug-induced hepatitis	contraindication	235876009
Peripheral nerve disease	contraindication	302226006
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.28	acidic
pKa2	0.0	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucose-6-phosphate 1-dehydrogenase	Enzyme	P11413	G6PD_HUMAN					WOMBAT-PK
CDGSH iron-sulfur domain-containing protein 1	Unclassified	Q9NZ45	CISD1_HUMAN		Ki	6.09		CHEMBL

External reference:

ID	Source
4018849	VUID
N0000147151	NUI
D00439	KEGG_DRUG
54-87-5	SECONDARY_CAS_RN
17140-81-7	SECONDARY_CAS_RN
4018848	VANDF
4018849	VANDF
C0028156	UMLSCUI
CHEBI:71415	CHEBI
U6Z	PDB_CHEM_ID
CHEMBL572	ChEMBL_ID
DB00698	DRUGBANK_ID
CHEMBL1201000	ChEMBL_ID
D009582	MESH_DESCRIPTOR_UI
6604200	PUBCHEM_CID
10917	IUPHAR_LIGAND_ID
488	INN_ID
927AH8112L	UNII
221129	RXNORM
181427	MMSL
2320	MMSL
404	MMSL
5179	MMSL
5180	MMSL
5181	MMSL
d00112	MMSL
002852	NDDF
002853	NDDF
002854	NDDF
373543005	SNOMEDCT_US
37978007	SNOMEDCT_US
426476003	SNOMEDCT_US
427332002	SNOMEDCT_US
85343003	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1643	CAPSULE	50 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0115-1645	CAPSULE	100 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2023	CAPSULE	50 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0115-2024	CAPSULE	100 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	0185-0122	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0440-1866	CAPSULE	100 mg	ORAL	ANDA	26 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0472-1992	SUSPENSION	25 mg	ORAL	ANDA	19 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3684	CAPSULE	25 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3684	CAPSULE	25 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3685	CAPSULE	50 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3685	CAPSULE	50 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3686	CAPSULE	100 mg	ORAL	ANDA	21 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	1	0591-3686	CAPSULE	100 mg	ORAL	ANDA	21 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7025	CAPSULE	100 mg	ORAL	ANDA	13 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7026	CAPSULE	50 mg	ORAL	ANDA	13 sections
nitrofurantoin macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	0904-7136	CAPSULE	100 mg	ORAL	NDA	25 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	10544-086	CAPSULE	75 mg	ORAL	NDA	28 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	10544-086	CAPSULE	25 mg	ORAL	NDA	28 sections
Nitrofurantoin Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	10544-601	CAPSULE	100 mg	ORAL	ANDA	24 sections
Nitrofurantion Macrocrystals	HUMAN PRESCRIPTION DRUG LABEL	1	12634-415	CAPSULE	100 mg	ORAL	NDA	24 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	2	13811-719	CAPSULE	25 mg	ORAL	ANDA	25 sections
Nitrofurantoin	HUMAN PRESCRIPTION DRUG LABEL	2	13811-719	CAPSULE	75 mg	ORAL	ANDA	25 sections
Nitrofurantoin	Human Prescription Drug Label	1	16571-740	SUSPENSION	25 mg	ORAL	NDA AUTHORIZED GENERIC	19 sections
NITROFURANTOIN MACROCRYSTALS	HUMAN PRESCRIPTION DRUG LABEL	1	16590-380	CAPSULE	100 mg	ORAL	ANDA	24 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	16714-439	CAPSULE	75 mg	ORAL	ANDA	23 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	16714-439	CAPSULE	25 mg	ORAL	ANDA	23 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	21695-300	CAPSULE	75 mg	ORAL	ANDA	27 sections
Nitrofurantoin (monohydrate/macrocrystals)	HUMAN PRESCRIPTION DRUG LABEL	2	21695-300	CAPSULE	25 mg	ORAL	ANDA	27 sections
Nitrofurantoin Monohydrate/ Macrocrystalline	HUMAN PRESCRIPTION DRUG LABEL	2	33261-160	CAPSULE	75 mg	ORAL	NDA	28 sections